161 related articles for article (PubMed ID: 8098233)
1. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
[TBL] [Abstract][Full Text] [Related]
3. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
4. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
6. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.
Müller MR; Lennartz K; Boogen C; Nowrousian MR; Rajewsky MF; Seeber S
Ann Hematol; 1992 Nov; 65(5):206-12. PubMed ID: 1360820
[TBL] [Abstract][Full Text] [Related]
9. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
10. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
12. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
13. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
15. Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.
Rivoltini L; Colombo MP; Supino R; Ballinari D; Tsuruo T; Parmiani G
Int J Cancer; 1990 Oct; 46(4):727-32. PubMed ID: 1976601
[TBL] [Abstract][Full Text] [Related]
16. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
17. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
19. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
20. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
